Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity. Issue 2 (19th September 2022) - Calabrese, Cassandra; Kirchner, Elizabeth; Villa-Forte, Alexandra; Hajj-Ali, Rula A; Moss, Brandon P; Fernandez, James P; Calabrese, Leonard